home / stock / cmvlf / cmvlf quote
Last: | $2.54 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $2.54 |
High: | $0 |
Low: | $0 |
Volume: | 8 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.54 | $0 | $2.54 | $0 | $0 | 8 | 06-21-2024 |
$2.54 | $0 | $2.54 | $0 | $0 | 8 | 06-18-2024 |
$2.54 | $0 | $2.54 | $0 | $0 | 68 | 05-30-2024 |
$2.54 | $0 | $2.54 | $0 | $0 | 32 | 05-24-2024 |
$2.54 | $2.54 | $2.54 | $2.54 | $2.54 | 200 | 05-21-2024 |
$2.96 | $0 | $2.96 | $0 | $0 | 30 | 05-20-2024 |
$2.96 | $2.96 | $2.96 | $2.96 | $2.96 | 285 | 05-16-2024 |
$2.6 | $0 | $2.6 | $0 | $0 | 45 | 05-06-2024 |
$2.6 | $0 | $2.6 | $0 | $0 | 40 | 04-18-2024 |
$2.6 | $2.6 | $2.6 | $2.6 | $2.6 | 500 | 04-02-2024 |
$2.59 | $2.48 | $2.59 | $2.59 | $2.48 | 400 | 03-21-2024 |
$2.59 | $0 | $2.59 | $0 | $0 | 1 | 03-18-2024 |
$2.59 | $2.59 | $2.59 | $2.59 | $2.59 | 100 | 03-14-2024 |
$2.63 | $2.75 | $2.63 | $2.79 | $2.63 | 400 | 03-08-2024 |
$2.35 | $2.42 | $2.35 | $2.42 | $2.35 | 300 | 03-05-2024 |
$2.56 | $2.46 | $2.56 | $2.56 | $2.46 | 200 | 03-01-2024 |
$2.66 | $2.66 | $2.66 | $2.66 | $2.66 | 200 | 02-27-2024 |
$2.8 | $2.71 | $2.8 | $2.8 | $2.71 | 500 | 02-21-2024 |
$3.09 | $3.04 | $3.09 | $3.09 | $3.04 | 200 | 02-08-2024 |
$2.95 | $2.8744 | $2.95 | $2.95 | $2.8744 | 300 | 01-29-2024 |
News, Short Squeeze, Breakout and More Instantly...
Cellectis Romainville Ord Company Name:
CMVLF Stock Symbol:
OTCMKTS Market:
Cellectis Romainville Ord Website:
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...
NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publicatio...